See more : ASMPT Limited (ASMVF) Income Statement Analysis – Financial Results
Complete financial analysis of Lepu Medical Technology (Beijing) Co., Ltd. (300003.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lepu Medical Technology (Beijing) Co., Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
- Manaksia Steels Limited (MANAKSTEEL.NS) Income Statement Analysis – Financial Results
- Civmec Limited (P9D.SI) Income Statement Analysis – Financial Results
- Bharti Hexacom Limited (BHARTIHEXA.NS) Income Statement Analysis – Financial Results
- TransDigm Group Incorporated (TDG) Income Statement Analysis – Financial Results
- Cocrystal Pharma Inc (8CC1.DU) Income Statement Analysis – Financial Results
Lepu Medical Technology (Beijing) Co., Ltd. (300003.SZ)
About Lepu Medical Technology (Beijing) Co., Ltd.
Lepu Medical Technology (Beijing) Co., Ltd. develops, produces, and sells medical devices and equipment. The company offers cardiovascular interventional products, such as coronary stents and balloons, catheters, guide wires, introducer sheaths, tourniquets, inflation devices, and PCI accessories; structural heart diseases products, including occluders, vascular plugs, delivery systems, and mechanical heart valves; cardiac rhythm management products, which include pacemakers, equipment, leads, and electrophysiology; off-pump coronary artery bypass grafting surgical cardiology products; and PTA balloons and guide wires peripheral interventional products. It also provides critical care products, such as vascular access products, needle free connectors, blood samplers, and pressure transducers; floor and suspended type digital subtraction angiography systems; in vitro diagnostic equipment and biomarkers; hemodialysis catheters and hollow fiber dialyzers; and general surgery products, including surgical staplers and endo surgery accessories. In addition, the company offers cardiovascular system drugs, such as antithrombotic, hypolipidemic, antihypertensive, antianginal, and heart failure treatment; ß-lactamase antibiotics and antifungal antimicrobial drugs; central nervous system drugs comprises painkillers and antidepressants; gastric/duodenal ulcer and chronic liver disease treatment drugs; respiratory system drugs; hypoproteinemia drugs; and activating blood circulation drugs. Further, it provides precision medicine, ECG telemonitoring, and cardiovascular disease consulting and management center services; medical S&T incubation and equity investment, and medical financial services; consultation, online pharmacy, and household medical equipment services; smart devices; and specialized hospital services for cardiovascular diseases, as well as involved in the co-construction of Cath lab. The company was founded in 1999 and is headquartered in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.98B | 10.61B | 10.66B | 8.04B | 7.80B | 6.36B | 4.54B | 3.47B | 2.77B | 1.67B | 1.30B | 1.02B | 919.85M | 770.10M | 565.20M | 393.88M | 298.98M | 175.34M |
| Cost of Revenue | 2.98B | 3.98B | 4.16B | 2.65B | 2.17B | 1.73B | 1.49B | 1.35B | 1.24B | 608.28M | 403.77M | 212.03M | 160.64M | 131.53M | 103.25M | 84.39M | 74.20M | 50.94M |
| Gross Profit | 5.00B | 6.63B | 6.50B | 5.38B | 5.63B | 4.62B | 3.05B | 2.11B | 1.53B | 1.06B | 899.49M | 803.89M | 759.20M | 638.57M | 461.95M | 309.49M | 224.79M | 124.40M |
| Gross Profit Ratio | 62.63% | 62.46% | 61.01% | 66.99% | 72.23% | 72.75% | 67.23% | 60.95% | 55.32% | 63.55% | 69.02% | 79.13% | 82.54% | 82.92% | 81.73% | 78.58% | 75.18% | 70.95% |
| Research & Development | 879.42M | 957.06M | 907.94M | 736.13M | 543.91M | 376.17M | 234.75M | 168.64M | 110.11M | 73.02M | 72.34M | 53.63M | 32.84M | 26.96M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 270.52M | 224.38M | 293.52M | 178.39M | 211.26M | 185.55M | 115.47M | 86.39M | 70.47M | 37.99M | 44.33M | 31.37M | 22.03M | 18.17M | 57.65M | 40.82M | 33.99M | 12.96M |
| Selling & Marketing | 853.45M | 2.03B | 2.11B | 1.84B | 2.17B | 1.87B | 1.06B | 638.06M | 432.17M | 341.34M | 296.83M | 226.09M | 148.53M | 114.34M | 82.43M | 70.47M | 45.65M | 29.70M |
| SG&A | 2.47B | 2.26B | 2.40B | 2.02B | 2.38B | 2.05B | 1.18B | 724.44M | 502.65M | 379.33M | 341.15M | 257.46M | 170.56M | 132.51M | 140.08M | 111.29M | 79.64M | 42.66M |
| Other Expenses | 104.90M | 552.19M | 489.08M | 457.58M | 443.11M | 31.47M | 39.76M | 28.99M | 20.02M | 20.11M | 11.02M | 13.48M | 5.58M | 3.35M | 3.95M | 1.19M | 811.35K | -433.00K |
| Operating Expenses | 3.45B | 3.77B | 3.80B | 3.21B | 3.37B | 2.83B | 1.73B | 1.16B | 810.23M | 542.47M | 483.29M | 362.63M | 248.69M | 189.49M | 141.27M | 111.49M | 79.99M | 44.50M |
| Cost & Expenses | 6.43B | 7.75B | 7.96B | 5.86B | 5.54B | 4.56B | 3.21B | 2.52B | 2.05B | 1.15B | 887.07M | 574.67M | 409.33M | 321.02M | 244.52M | 195.88M | 154.19M | 95.44M |
| Interest Income | 115.34M | 87.99M | 57.59M | 43.16M | 44.35M | 48.68M | 28.06M | 15.50M | 9.51M | 12.19M | 19.29M | 28.55M | 26.90M | 22.70M | 6.93M | 4.63M | -0.59 | 0.00 |
| Interest Expense | 170.65M | 188.78M | 228.49M | 268.92M | 321.70M | 276.35M | 111.40M | 76.11M | 45.30M | 1.23M | 445.60K | 209.42K | 0.00 | 238.95K | 589.41K | 172.20K | 1.26M | 0.00 |
| Depreciation & Amortization | 603.78M | 567.64M | 521.57M | 443.13M | 325.06M | 267.02M | 224.61M | 174.88M | 131.61M | 66.65M | 51.40M | 35.43M | 23.84M | 16.69M | 13.30M | 10.38M | 5.89M | 1.83M |
| EBITDA | 2.36B | 3.47B | 2.84B | 3.07B | 2.67B | 1.98B | 1.51B | 1.13B | 836.84M | 612.85M | 498.82M | 476.69M | 566.84M | 489.58M | 345.05M | 208.38M | 150.69M | 81.73M |
| EBITDA Ratio | 29.55% | 31.68% | 26.67% | 36.28% | 39.07% | 35.22% | 34.55% | 33.53% | 32.43% | 37.04% | 38.17% | 47.58% | 62.16% | 63.92% | 61.02% | 53.71% | 50.65% | 46.86% |
| Operating Income | 1.55B | 2.62B | 2.14B | 2.15B | 2.76B | 1.44B | 1.16B | 864.21M | 684.04M | 516.86M | 420.97M | 466.46M | 537.42M | 469.35M | 327.48M | 200.51M | 149.50M | 79.94M |
| Operating Income Ratio | 19.39% | 24.72% | 20.12% | 26.74% | 35.42% | 22.69% | 25.47% | 24.92% | 24.71% | 30.98% | 32.30% | 45.92% | 58.43% | 60.95% | 57.94% | 50.91% | 50.00% | 45.59% |
| Total Other Income/Expenses | 7.28M | -11.36M | 1.55M | 54.14M | -698.00M | 31.47M | 39.76M | 23.88M | 8.10M | 19.77M | 10.99M | 41.59M | 5.58M | 25.85M | 10.55M | 1.19M | 811.35K | -433.00K |
| Income Before Tax | 1.55B | 2.61B | 2.15B | 2.20B | 2.06B | 1.47B | 1.20B | 890.96M | 700.94M | 536.64M | 431.96M | 479.83M | 543.00M | 472.65M | 331.42M | 201.70M | 150.31M | 79.51M |
| Income Before Tax Ratio | 19.48% | 24.62% | 20.13% | 27.41% | 26.47% | 23.19% | 26.35% | 25.69% | 25.32% | 32.16% | 33.14% | 47.23% | 59.03% | 61.37% | 58.64% | 51.21% | 50.28% | 45.34% |
| Income Tax Expense | 262.15M | 367.09M | 365.73M | 326.23M | 339.46M | 219.04M | 201.79M | 144.25M | 104.95M | 84.40M | 65.31M | 76.50M | 69.85M | 62.01M | 39.07M | 534.54K | 589.48K | 15.91M |
| Net Income | 1.26B | 2.20B | 1.72B | 1.80B | 1.73B | 1.22B | 899.09M | 679.26M | 520.89M | 423.19M | 361.65M | 403.27M | 473.16M | 410.48M | 292.21M | 201.37M | 149.73M | 63.60M |
| Net Income Ratio | 15.77% | 20.77% | 16.13% | 22.42% | 22.13% | 19.17% | 19.81% | 19.59% | 18.81% | 25.36% | 27.75% | 39.70% | 51.44% | 53.30% | 51.70% | 51.12% | 50.08% | 36.27% |
| EPS | 0.68 | 1.22 | 0.96 | 1.01 | 0.97 | 0.68 | 0.51 | 0.39 | 0.32 | 0.26 | 0.22 | 0.25 | 0.29 | 0.25 | 0.19 | 0.14 | 0.12 | 0.13 |
| EPS Diluted | 0.68 | 1.21 | 0.95 | 1.01 | 0.97 | 0.68 | 0.51 | 0.39 | 0.32 | 0.26 | 0.22 | 0.25 | 0.29 | 0.25 | 0.19 | 0.14 | 0.12 | 0.13 |
| Weighted Avg Shares Out | 1.86B | 1.80B | 1.79B | 1.78B | 1.77B | 1.78B | 1.78B | 1.74B | 1.62B | 1.62B | 1.62B | 1.62B | 1.62B | 1.62B | 1.50B | 1.46B | 1.21B | 486.71M |
| Weighted Avg Shares Out (Dil) | 1.86B | 1.82B | 1.81B | 1.78B | 1.77B | 1.78B | 1.78B | 1.74B | 1.62B | 1.62B | 1.62B | 1.62B | 1.62B | 1.62B | 1.50B | 1.46B | 1.21B | 486.71M |
Source: https://incomestatements.info
Category: Stock Reports